Seattle Genetics   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Bothell WA United States (1997)
Status: Acquired by Merck (2022)

Organization Overview

First Clinical Trial
2000
NCT00031187
First Marketed Drug
2011
brentuximab vedotin (adcetris)
First NDA Approval
2011
brentuximab vedotin (adcetris)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SEAGEN | Seagen Inc. | Seattle Genetics, | SEATTLE GENETICS | Seattle Genetics, Inc. | Seattle Genetics Medical Monitor